Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer

Takeshi Masuda, Taizo Hirata, Tomohiro Sakamoto, Yukari Tsubata, Eiki Ichihara, Toshiyuki Kozuki, Hiroyasu Shoda, Masanori Motonaga, Takako Yoshida, Miki Fukutani, Kazue Tsuji-Takayama, Atsushi Tamura, Harunobu Amagase, Hideki Fujihara, Gaku Aoki, Tomoyuki Akita, Yasushi Orihashi, Toshio Miyata, Noboru Hattori

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer'. Together they form a unique fingerprint.

Medicine and Dentistry

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science